Design and expression of a dimeric form of human immunodeficiency virus type 1 antibody 2G12 with increased neutralization potency

Journal of Virology

Volumn 83, Issue 1, 2009, Pages 98-104

  West Jr , Anthony P ^a   Galimidi, Rachel P ^a   Foglesong, Christopher P ^a   Gnanapragasam, Priyanthi N P ^a   Huey Tubman, Kathryn E ^a   Klein, Joshua S ^a   Suzuki, Maria D ^a   Tiangco, Noreen E ^a   Vielmetter, Jost ^a   Bjorkman, Pamela J ^a  

^a CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; EPITOPE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; MONOCLONAL ANTIBODY;

ANTIBODY STRUCTURE; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR MODEL; MOLECULAR RECOGNITION; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; VIRUS MUTANT; VIRUS STRAIN; AMINO ACID SUBSTITUTION; CHEMICAL STRUCTURE; DIMERIZATION; GENETICS; IC 50; IMMUNOLOGY; MISSENSE MUTATION; PROTEIN BINDING; SERODIAGNOSIS; SURFACE PLASMON RESONANCE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID SUBSTITUTION; ANTIBODIES, MONOCLONAL; DIMERIZATION; HIV ANTIBODIES; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MUTATION, MISSENSE; NEUTRALIZATION TESTS; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; SURFACE PLASMON RESONANCE;

EID: 58149376504     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01564-08     Document Type: Article

References (24)

1. Bennett, M. J., and D. Eisenberg. 2004. The evolving role of 3D domain swapping in proteins. Structure 12:1339-1341.
2. Burton, D. R., R. L. Stanfield, and I. A. Wilson. 2005. Antibody versus HIV in a clash of evolutionary titans. Proc. Natl. Acad. Sci. USA 102:14943-14948.
3. Calarese, D. A., H. K. Lee, C. Y. Huang, M. D. Best, R. D. Astronomo, R. L. Stanfield, H. Katinger, D. R. Burton, C. H. Wong, and I. A. Wilson. 2005. Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc. Natl. Acad. Sci. USA 102:13372-13377.
4. Calarese, D. A., C. N. Scanlan, M. B. Zwick, S. Deechongkit, Y. Mimura, R. Kunert, P. Zhu, M. R. Wormald, R. L. Stanfield, K. H. Roux, J. W. Kelly, P. M. Rudd, R. A. Dwek, H. Katinger, D. R. Burton, and I. A. Wilson. 2003. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300:2065-2071.
5. Durocher, Y., S. Perret, and A. Kamen. 2002. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res. 30:E9.
6. Harris, L. J., S. B. Larson, K. W. Hasel, and A. McPherson. 1997. Refined structure of an intact IgG2a monoclonal antibody. Biochemistry 36:1581-1597.
7. Harris, L. J., E. Skaletsky, and A. McPherson. 1998. Crystallographic structure of an intact IgG1 monoclonal antibody. J. Mol. Biol. 275:861-872.
8. Huber, A. H., R. F. Kelley, L. N. Gastinel, and P. J. Bjorkman. 1993. Crystallization and stoichiometry of binding of a complex between a rat intestinal Fc receptor and Fc. J. Mol. Biol. 230:1077-1083.
9. Janeway, C. A., P. Travers, M. Walport, and M. J. Schlomchik. 2005. Immunobiology, 6th ed. Garland Science Publishing, New York, NY.
10. Jones, T. A., J. Y. Zou, S. W. Cowan, and M. Kjeldgaard. 1991. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47(Pt. 2):110-119.
11. Kabat, E. A., T. T. Wu, H. M. Perry, K. S. Gottesman, and C. Foeller. 1991. Sequences of proteins of immunological interest. Department of Health and Human Services, Washington, DC.
12. Li, M., F. Gao, J. R. Mascola, L. Stamatatos, V. R. Polonis, M. Koutsoukos, G. Voss, P. Goepfert, P. Gilbert, K. M. Greene, M. Bilska, D. L. Kothe, J. F. Salazar-Gonzalez, X. Wei, J. M. Decker, B. H. Hahn, and D. C. Montefiori. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79:10108-10125.
13. Mehandru, S., B. Vcelar, T. Wrin, G. Stiegler, B. Joos, H. Mohri, D. Boden, J. Galovich, K. Tenner-Racz, P. Racz, M. Carrington, C. Petropoulos, H. Katinger, and M. Markowitz. 2007. Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J. Virol. 81:11016-11031.
14. Montefiori, D. C. 2005. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr. Protoc. Immunol. Chapter 12:Unit 12.11.
15. Ramessar, K., T. Rademacher, M. Sack, J. Stadlmann, D. Platis, G. Stiegler, N. Labrou, F. Altmann, J. Ma, E. Stoger, T. Capell, and P. Christou. 2008. Cost-effective production of a vaginal protein microbicide to prevent HIV transmission. Proc. Natl. Acad. Sci. USA 105:3727-3732.
16. Roux, K. H., P. Zhu, M. Seavy, H. Katinger, R. Kunert, and V. Seamon. 2004. Electron microscopic and immunochemical analysis of the broadly neutralizing HIV-1-specific, anti-carbohydrate antibody, 2G12. Mol. Immunol. 41:1001-1011.
17. Saphire, E. O., P. W. Parren, R. Pantophlet, M. B. Zwick, G. M. Morris, P. M. Rudd, R. A. Dwek, R. L. Stanfield, D. R. Burton, and I. A. Wilson. 2001. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 293:1155-1159.
18. Scanlan, C. N., R. Pantophlet, M. R. Wormald, E. Ollmann Saphire, R. Stanfield, I. A. Wilson, H. Katinger, R. A. Dwek, P. M. Rudd, and D. R. Burton. 2002. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of α1→2 mannose residues on the outer face of gp120. J. Virol. 76:7306-7321.
19. Sheskin, D. 2004. Handbook of parametric and nonparametric statistical procedures, 3rd ed. Chapman & Hall/CRC, Boca Raton, FL.
20. Stiegler, G., C. Armbruster, B. Vcelar, H. Stoiber, R. Kunert, N. L. Michael, L. L. Jagodzinski, C. Ammann, W. Jager, J. Jacobson, N. Vetter, and H. Katinger. 2002. Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation. AIDS 16:2019-2025.
21. Trkola, A., H. Kuster, P. Rusert, B. Joos, M. Fischer, C. Leemann, A. Manrique, M. Huber, M. Rehr, A. Oxenius, R. Weber, G. Stiegler, B. Vcelar, H. Katinger, L. Aceto, and H. F. Gunthard. 2005. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11:615-622.
22. Trkola, A., M. Purtscher, T. Muster, C. Ballaun, A. Buchacher, N. Sullivan, K. Srinivasan, J. Sodroski, J. P. Moore, and H. Katinger. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70:1100-1108.
23. Wei, X., J. M. Decker, S. Wang, H. Hui, J. C. Kappes, X. Wu, J. F. Salazar-Gonzalez, M. G. Salazar, J. M. Kilby, M. S. Saag, N. L. Komarova, M. A. Nowak, B. H. Hahn, P. D. Kwong, and G. M. Shaw. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312.
24. Wolbank, S., R. Kunert, G. Stiegler, and H. Katinger. 2003. Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12. J. Virol. 77:4095-4103.